Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
41-60 of 998 trials

Heart Failure in Children: Vericiguat Study

We are studying a new medication, vericiguat, to see if it helps improve heart function in children with heart failure. The trial compares its effects to a placebo to ensure safety and effectiveness.

Chronic Systolic Heart FailureEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Pembrolizumab for Children with Advanced Melanoma and Solid Tumors

We are studying the safety and effectiveness of pembrolizumab in children with advanced melanoma or certain relapsed solid tumors and lymphoma. This trial aims to understand how well this treatment works and its potential side effects.

Advanced Melanoma and Related CancersSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Brexucabtagene Autoleucel for Rare B-cell Malignancies

We are studying a new treatment for adults with relapsed or refractory Richter Transformation of B-cell malignancies. The goal is to see if it improves response rates and overall survival compared to existing options.

Relapsed/Refractory Richter Transformation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Severe Eosinophilic Asthma: Benralizumab for Kids

We are studying whether benralizumab can help children with severe eosinophilic asthma by reducing asthma attacks and improving their symptoms. This trial will also look at the safety of the medication.

Severe Eosinophilic Asthma>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyPulmonology

Severe Pneumonia: Testing Trimodulin

We are studying whether trimodulin can improve survival in hospitalized adults with severe pneumonia compared to a placebo. The trial also looks at the safety and effects of the treatment.

Community Acquired PneumoniaConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Axial Spondyloarthritis: Filgotinib Study

We are testing the medication filgotinib in adults with active axial spondyloarthritis to see if it improves symptoms and physical function compared to a placebo. The study also looks at the safety of this treatment.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

COVID-19 Treatment: Antiviral Therapy for Immunocompromised Patients

We are studying a combination of antiviral medications to see if it helps immunocompromised patients recover from COVID-19 more effectively. The goal is to improve viral clearance and reduce symptoms compared to standard treatments.

Covid-193-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Heart Attack Recovery: Milvexian Study

We are testing a new oral medication, milvexian, to see if it helps reduce the risk of further heart problems in patients after a heart attack. This study compares milvexian to a placebo alongside standard treatment.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

NonAdvanced Systemic Mastocytosis: Bezuclastinib Study

We are testing a new oral medication, bezuclastinib, to see if it is effective and safe for patients with NonAdvanced Systemic Mastocytosis. This study compares the medication to a placebo to understand its potential benefits.

Systemic Mastocytosis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Dexamethasone for Moderate to Severe Depression

We are studying whether adding dexamethasone to standard depression treatment can improve symptoms for those with moderate to severe depression. This trial aims to assess its safety and effectiveness.

Depression6-12 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Advanced Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab Study

We are studying whether a combination of Fianlimab and Cemiplimab is more effective than Cemiplimab alone for adults with advanced non-small cell lung cancer. This trial focuses on patients whose tumors express PD-L1 at high levels.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPartially RemoteOncology

Osimertinib (TAGRISSO) Continuation Study

We are providing ongoing treatment with osimertinib for patients who have benefited from it in a previous study. The goal is to monitor safety and tolerability as they continue their treatment.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Serious Bacterial Infections in Children: Aztreonam-Avibactam Study

We are investigating a new treatment for serious gram-negative bacterial infections in children aged 9 months to under 18 years. The study compares this treatment to the best available therapy to assess safety and effectiveness.

Hospital-Acquired PneumoniaVentilator-Associated PneumoniaComplicated Gram-Negative Bacterial Infections≤3 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPediatrics

Kidney Transplant: Belatacept vs. Calcineurin Inhibitors

We are studying whether switching to a new immunosuppressive medication helps adolescent kidney transplant recipients maintain their health better than staying on their current treatment. This trial focuses on patients aged 12 to under 18 years.

Kidney Transplant>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Continued Treatment with Parsaclisib for Blood Disorders

We are providing ongoing treatment for patients who have previously participated in studies of parsaclisib. The goal is to evaluate the safety of this medication alone or with other therapies.

Advanced CancerAutoimmune Hemolytic AnemiaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

COVID-19 Treatment: LTX-109 Nasal Spray Study

We are testing a new nasal spray for people with COVID-19 or similar symptoms to see if it helps them recover faster and clear the virus. The study will also monitor safety and overall wellbeing during treatment.

Respiratory Tract InfectionCOVID-19COVID-like Illness≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Metreleptin for Young Children with Generalized Lipodystrophy

We are studying whether metreleptin can help children under 6 years old with generalized lipodystrophy and related diabetes. The trial will also look at its effects on quality of life and other health markers.

Generalized Lipodystrophy1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyEndocrinology

Psilocybin for Hospitalized Patients with Treatment-Resistant Depression

We are studying the safety and feasibility of psilocybin-assisted psychotherapy for patients with treatment-resistant depression in a hospital setting. This research aims to explore its effects on depression and the overall experience of patients.

Treatment-Resistant DepressionEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry

Takotsubo Syndrome: New Treatment Approaches

We are studying whether a combination of adenosine and dipyridamole improves outcomes for patients with Takotsubo Syndrome. Additionally, we’re testing if apixaban can lower the risk of blood clots in these patients.

Takotsubo Syndrome>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteCardiologyInternal Medicine

Generalized Myasthenia Gravis: Ravulizumab for Kids

We are studying the effects of Ravulizumab in children with Generalized Myasthenia Gravis to see how well it works and its safety. This trial will help us understand if it improves their quality of life.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics